The recombinant therapeutic antibodies and proteins market has gained significant traction in the recent years. Recombinant therapeutic antibodies and proteins are widely used in various immunotherapy applications for treatment of chronic illnesses like cancer and autoimmune disorders. They have comparatively less side effects than other traditional drug therapies and help target specific cells in the body.
Market key trends:
Increasing R&D investments by major players is driving the recombinant therapeutic antibodies and proteins market. Leading biopharma companies are heavily investing in developing novel monoclonal antibodies and biologics for treatment of various chronic diseases. For instance, Amgen invested over US$ 4 billion in R&D during 2021 with focus on expanding its pipeline of novel antibodies and biologics. The increasing R&D expenditures are helping companies launch innovative antibody therapeutics with improved efficacy and reduced side effects, thereby accelerating the market growth over the forecast period.
Segment Analysis
The recombinant therapeutic antibodies and proteins market can be segmented based on product type, application, and end user. By product type, monoclonal antibodies currently dominate the market due to their high specificity and affinity for antigens. The monoclonal antibodies segment accounts for more than 60% of the total market share owing to the increasing use of monoclonal antibodies for treatment of various cancers and autoimmune disorders.
Key Takeaways
Global Recombinant Therapeutic Antibodies And Proteins Market is expected to witness high growth.
Regional analysis: North America currently holds the largest share of the recombinant therapeutic antibodies and proteins market due to established healthcare infrastructure and higher adoption of advanced treatment options. However, Asia Pacific is expected to grow at the fastest pace during the forecast period due advances being made in biologics development and rising healthcare spending in emerging countries such as China and India.
Key players: Key players operating in the recombinant therapeutic antibodies and proteins market include Amgen, Hoffmann-La Roche, AbbVie, Johnson & Johnson, Bristol-Myers Squibb, Novo Nordisk, Eli Lilly, Sanofi, Pfizer, Novartis, Merck, AstraZeneca, GlaxoSmithKline, and Takeda Pharmaceutical. Amgen dominated the overall market in 2021 owing to its wide product portfolio and strong presence across major markets. However, the market is highly competitive with presence of both international and local players.
Get More Insights On This Topic: https://www.trendingwebwire.com/the-recombinant-therapeutic-antibodies-and-proteins-market-driven-by-growing/
Explore More Related Article: https://masstamilan.tv/naloxone-life-saving-drug-in-opioid-overdose/
Comments
0 comment